—A recent study suggests that perimenopausal and postmenopausal women report worse bladder health and function compared to their premenopausal counterparts. Additionally, current hormone use was ...
Avelumab plus BSC significantly improved OS and PFS in advanced urothelial carcinoma patients, irrespective of diabetes status, as shown in the JAVELIN Bladder 100 trial. The trial's findings led to ...
Bavencio shows efficacy and safety in advanced urothelial carcinoma, regardless of diabetes status, as per JAVELIN Bladder 100 trial findings. Diabetes requires careful management in patients ...
100% (n=7) of evaluable patients (1 CIS, 6 Ta/T1) achieved disease free status. One of these patients was re-treated at 3 months. “I am impressed by these promising NDV-01 data reported at AUA2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results